Esmo 2019 – thyroid results strengthen selpercatinib's case
As selpercatinib confirms its activity in thyroid cancer, Eli Lilly gears up to prove the Ret inhibitor’s potential in larger trials.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
World Lung 2019 – Lilly celebrates a win with first Loxo asset
Impressive results in lung cancer with Eli Lilly’s Ret inhibitor set the stage for approval next year, but Blueprint is not far behind.
Deciphera hopes Invictus win will be just the beginning
Positive data should pave the way for ripretinib’s approval in fourth-line GIST, but investors are already eyeing a bigger opportunity.
Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Deciphera nears its biggest test
The small-molecule oncology player zeroes in on its first commercial opportunity.
JP Morgan 2019 day one roundup – happy days are here again
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
JP Morgan 2019 – Lilly fans the M&A flames with Loxo Oncology deal
Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Vitrakvi and LOXO-195 with Bayer.
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.